FDA
-
-
-
-
-
-
-
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
-
-
-
-
-
-
-
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
-
-
-
-
-
-
-
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
H.C. Wainwright Upgrades Dogwood Therapeutics, Inc. (DWTX) to Buy
-
-
-
-
-
-
-
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
-
-
-
-
-
-
-
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
-
326,714 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

